Cohen & Steers Global Realty Majors ETF (GRI): Price and Financial Metrics ETF
GRI Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $0.43 | 52-week high | $62.23 |
| Prev. close | $0.44 | 52-week low | $0.41 |
| Day low | $0.42 | Volume | 25,000 |
| Day high | $0.44 | Avg. volume | 602,751 |
| 50-day MA | $0.72 | Dividend yield | N/A |
| 200-day MA | $7.44 |
GRI Stock Price Chart Interactive Chart >
Cohen & Steers Global Realty Majors ETF (GRI) ETF Bio
The investment objective of the Cohen & Steers Global Realty Majors ETF seeks to benefit from the potentially substantial and growing long-term income streams and diversification benefits that global real estate securities and REIT structures may provide.
GRI ETF Info
| Issuer | |
| Expense Ratio | % |
| Asset Class | |
| Sector | Global Real Estate ETFs |
| Assets Under Management (AUM) | N/A |
| Net Asset Value (NAV) | $0.00 |
| Options? | No |
| Total Holdings | N/A |
GRI Top Holdings
| Symbol | Company | % of Total |
Latest GRI News From Around the Web
Below are the latest news stories about GRI BIO INC that investors may wish to consider to help them evaluate GRI as an investment opportunity.
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatmentGRI Bio CEO Marc Hertz joined Steve Darling from Proactive to share news the company has begun patient enrollment in a Phase 2a biomarker study focused on evaluating GRI-0621 as a potential treatme... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival1 LA JOLLA, CA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibroti |
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited compliance and no impact on survival1 Management discusses IND clearance and what this milestone means in a brief video: here LA JOLLA, CA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a |
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatePhase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on survival1 GRI-0803 systemic lupus erythematosus (“SLE”) program advancing towards completion of IND-enabling studies with IND filing on track for H1 2024 Annual prevalence estimated to be ~161,0 |
GRI Price Returns
| 1-mo | -44.59% |
| 3-mo | -79.19% |
| 6-mo | -94.61% |
| 1-year | -99.12% |
| 3-year | -99.86% |
| 5-year | -99.99% |
| YTD | -84.04% |
| 2023 | -95.57% |
| 2022 | -85.45% |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 21.55% |